Hey, all. This is Eric Christensen, pharmacist, host of the Real Life Pharmacology podcast.

Hope you're enjoying the show overall. If you're listening for the first time,

hopefully you can get some value out of this podcast, whether you're preparing for real life

or whether you're preparing for pharmacology exams or board exams.

So with that, let's get into the podcast.

We're going to cover River Roxaban today.

The brand name of that medication is Zarelto.

And this is an anticoagulant type medication.

This is one of the more common newer oral anticoagulants.

Riveroxaban and Apixaban, which I have done a podcast about,

are probably the two most commonly used new oral anticoagulants that I see.

And actually there was a recent update with AHA, ACC, and HRS in

their guidelines. And NOACs are now preferred. So those are the novel oral anticoagulants,

Riveroxban and Apixaband, as well as a couple others, too, that aren't used quite as often.

But these drugs are now preferred over warfarin in the majority of situations in atrophibulation when we're trying to prevent stroke.

There's a couple exceptions like mitral stenosis as well as potentially

artificial valves as well. But overall, in the majority of cases, these drugs are now preferred.

So that's an interesting update there. And how these drugs work, or at least how River Oximabon works,

is it prevents those clots by inhibiting factor 10A. So this is an important factor that's within

the clotting cascade and formation of clots. So factor 10-a is required for the conversion of

prothrombin to thrombin, and thrombin ultimately activates platelets and forms fibrin, which is

essential for clot formation. So by preventing, by inhibiting factor 10A,

...